Newsletter · 2026-08-31 · Ashutosh Agarwal

Investors Back Lilly Over Novo as Heart Data Reframes GLP-1 Drugs - The Obesity-Drug Pipeline - Week of August 31, 2026

Obesity-drug newsletter for the week of August 31, 2026. Investors make Eli Lilly their top pharma pick as its weight-loss pill gains on Novo Nordisk, new SURMOUNT-1 heart data reframes tirzepatide as a cardiometabolic drug, and a Medicare 50 dollar program plus direct-to-patient channels pull at net price.

The Obesity-Drug Pipeline

Week of August 31, 2026: Investors Back Lilly Over Novo as Heart Data Reframes GLP-1 Drugs

TL;DR (15 seconds)

• The investors finally spoke, and the verdict is that Lilly's pill is pulling ahead of Novo. A stock-picking podcast made Eli Lilly its "stock of the day," called it "clearly the top big pharma stock out there," and said its weight-loss pill "is gaining ground a little bit now on Novo Nordisk." A separate investing show flagged Novo's beaten-down stock as a possible bargain but warned about the 2030 patent cliff. Stock Market Today With IBD · Know Your Risk

• The strongest bull argument this fortnight was not about weight at all, it was about the heart. A cardiology podcast walked through new trial data showing that at the top dose, tirzepatide (the drug in Lilly's Zepbound and Mounjaro) cut a key inflammation marker by 55%, and argued these should be thought of as "cardiometabolic health drugs," not weight-loss drugs, with a benefit that could "far outdo statins." That reframe is exactly what turns obesity drugs into lifelong, insurance-covered prescriptions. This Week in Cardiology

• Same drugs, opposite vectors. The clinical thread is bullish for volume, while a Medicare 50 dollar program, direct-to-patient channels, and a black market Lilly cannot stamp out are bearish for price. The number that decides the whole thing, clean net revenue per patient per year, is still the one the podcasts never hand over.

How to read this issue: when a company executive or industry operator is speaking, we label them OPERATOR/INSIDER. When it is a journalist, analyst, clinician, or investor commenting from the outside, we label them ANALYST/PUNDIT. The threads below are drawn from podcasts aired August 10 to 20, each dated on the item.

What's new

1. Wall Street's own read: Lilly is the pharma to own, and its pill is catching Novo. The clearest investor voice came from the hosts of Stock Market Today With IBD (August 18, ANALYST/PUNDIT), who made Eli Lilly their "stock of the day." They called Lilly "a heavyweight... just a massive growth, continuing to grow," "clearly the top big pharma stock out there," and, the line that matters for the Lilly-versus-Novo scorecard, said "its weight loss pill is gaining ground a little bit now on Novo Nordis[k]. That was one area of weakness... I think that's one reason why it had a little bit of trouble a couple months ago."

The rest was trading mechanics worth knowing: Lilly fell about 3.6% that day in a broad AI-driven sell-off but "held the 50-day line," and the hosts suggested "buying stock in steps" rather than all at once, around the $1,200 level with a breakout toward $1,250. They also made a portfolio point that is easy to forget in an AI-obsessed market: Lilly is a lower-volatility name (a 3.4% average daily range versus the 9% to 15% swings of hot AI stocks) and works as "a good counterbalance to the portfolio." Bottom line from the Street: Lilly is a core hold, and the Novo gap is widening in Lilly's favor.

2. The bargain-hunter's case for Novo, and the one thing that kills it. On Know Your Risk (August 14), two investors (ANALYST/PUNDIT) looked at Novo Nordisk as a value idea. Their read: roughly "65%, 70% of their revenue is directly attributable to GLP-1s," the stock "has had some tar knocked out of it... recently," and what is left is "a pretty interesting proposition... a nice dividend, good-looking balance sheet." They admitted they were "late to the party."

But they put their finger on exactly why Novo is cheap: "the only thing to keep in mind is going to be that patent cliff that falls off whenever the competition really ramps... that's a tough thing with medicine is when it gets totally commodified." That is the whole bear case in one breath, and it is why they would rather play the theme sideways, through "second and third order effects." Their pick there was Stryker (SYK, ANALYST/PUNDIT view), the medical-device maker, which they like for aging-population tailwinds (joint replacements, hospital equipment), "13% to 15%" annual growth and "25% net margins." One host also volunteered that he personally "microdoses" a GLP-1 at "one-fifth to one-sixth of a normal prescription," a small but telling data point on how far off-label, low-dose use has spread among the wealthy and health-conscious.

3. A Fidelity portfolio manager: the muscle-loss problem is the next battleground, and the reason to bet on pills. On Fidelity Viewpoints: Market Sense (August 11), Fidelity biotech portfolio manager Irini (ANALYST/PUNDIT, a former Harvard neuroscientist) called GLP-1s "transformative" but zeroed in on the drawback that keeps showing up in this newsletter: "when you lose that amount of weight, 40% of that weight loss is not fat. 40% of it is lean muscle mass. And what is muscle? Muscle is our biggest metabolic organ." Her investment conclusion follows directly: she is "focused on... oral therapies, not injectable therapies, that curtail that nausea, but also let you keep that lean muscle mass," because "if you go off of a GLP-1, you need that muscle there" to keep the weight off.

She also gave useful color on the funding backdrop for the whole obesity-drug arms race: big pharma is "sitting on record piles of cash," facing "patent cliffs in 2030 that are insurmountable unless they fill their coffers" with biotech deals, and has "about a trillion in firepower right now" for acquisitions. The share of the biotech index (the XBI) made up of companies with real, selling products has risen to "40%," and she cited a Jefferies projection that it hits "75% by 2027." Translation for the book: expect the fast-follower names (Viking and others) to stay in play as buyout candidates.

4. The heart data that turns a diet drug into a lifelong prescription. This is the most thesis-relevant clinical item of the fortnight. On This Week in Cardiology (August 14), cardiologist Dr. John Mandrola (ANALYST/PUNDIT) walked through a new analysis (published in JACC) of the SURMOUNT-1 trial, tirzepatide versus placebo in people with obesity. At week 72, the 15 mg dose delivered "a 55% reduction in CRP" (C-reactive protein, a standard marker of inflammation), "a 30% reduction in IL-6, a 40% reduction in insulin resistance, 61% reduction in leptin," plus drops in blood pressure, cholesterol and triglycerides.

His takeaway is the one that matters for how these drugs get paid for: "these drugs should not be considered weight loss drugs, but cardiometabolic health drugs," and he predicts "this benefit is going to far outdo statins in the disease modification category." If doctors and payers accept that framing, GLP-1s stop being cosmetic and become preventive cardiology, the single biggest lever on long-term volume. Mandrola was careful with the caveats, and they are worth flagging: he "worry[s] there is a signal of harm" in patients with a weak-pumping form of heart failure (HFrEF), because these drugs raise heart rate, and he is "very worried about committing children and adolescents to these drugs." So: a powerful bull argument for the core adult market, with two clear boundaries on where it does not apply.

5. Lilly's war on the retatrutide black market, with real numbers. BioSpace's weekly (August 19), hosted by its editors (ANALYST/PUNDIT), put hard figures on something this newsletter has only referenced in passing. Retatrutide is Lilly's next-generation obesity drug, not yet approved, and so sought-after that a gray market has sprung up ahead of launch. Lilly is now fighting it aggressively: it "has sued six U.S. entities," "referred more than 200 other players to U.S. authorities," and "reported 14,000 websites, social media posts, advertisements, online listings" spanning "100 countries" for illegal sale of the drug. Lilly called it "an urgent public health crisis" that is "aided by criminal networks," and is leaning on everyone from "credit card companies" to "logistics companies" to choke off supply.

Why it matters: this is Lilly trying to protect the pricing and safety perimeter of its most important pipeline asset before it even launches. The same episode framed the current commercial fight cleanly too: "Novo Nordisk is selling more of their oral Wegovy, whereas Eli Lilly is kind of playing catch-up because they are entering [the oral] market with a molecule that consumers weren't as familiar with." So on today's oral pills, Novo has the brand edge; on tomorrow's most powerful molecule (retatrutide), Lilly is playing defense against copycats. Both are live battlegrounds.

6. A Novo insider tells the origin story, and quietly reminds you why the science keeps expanding the market. On Healthy Dialogue (August 20), Lotte Bjerre Knudsen, the Novo Nordisk scientist who invented liraglutide (OPERATOR/INSIDER), and academic gut-hormone pioneer Jens Holst (ANALYST/PUNDIT) traced the drugs from the lab (Knudsen "started working on GLP-1... in 1991," "three failed attempts" before the fatty-acid trick that made the first long-acting version stable) to today's blockbusters. Her line on the leap from Novo's first drug to its second: semaglutide "just turned out to give so much more weight loss. And that was what became the revolution in weight loss."

The investable nugget buried in the science: a "recent Gallup poll found about one in 10 U.S. adults are currently taking GLP-1s," a striking penetration number for a drug class critics keep calling a fad. And Knudsen laid out why the label keeps expanding into new diseases (heart, kidney, liver): there are GLP-1 receptors "expressed on many different cell types," and the drugs work through "three major mechanisms," weight loss "probably... more than 10%," direct effects on the blood-vessel system, and a "pronounced effect" on inflammation. On safety, she was measured: with a drug "used as widely as this one is, there's always going to be a rare side effect," but the regulators' benefit-risk verdict "has always come out positive."

7. The payer wildcard nobody circled: Medicare now has a $50 GLP-1 program. Buried in an operator interview was a genuinely important payer datapoint. On Off the Chart (August 13), the host noted, and the guest confirmed, that "Medicare just launched its own $50 GLP-1 program for some older patients through 2027." That is the government putting a cheap, fixed out-of-pocket price in front of a huge, previously-excluded population. It comes with a limit: as the guest stressed, it "doesn't reach working-age, commercially-insured patients," the bulk of the market.

The guest was Jay Bregman, CEO of Andel (OPERATOR/INSIDER), whose whole business is routing employers around the traditional insurance middlemen. His stat on how broken commercial access is: "less than 2% of people... in any given plan... actually get access to the GLP-1" even when it is nominally covered, because "there's massive utilization management, there's massive prior authorizations, people just give up." Andel buys brand-name drugs "directly from the manufacturer at a significantly lower price," launched "in March with ZepBound," and lets employers pay "as little as $100 per fill." Crucially, he confirmed "Eli Lilly and Novo Nordisk have each opened direct channels of their own," the drugmakers increasingly selling straight to patients and employers, cutting out the PBMs. For the CVS/Cigna/UnitedHealth read-through, that disintermediation trend is the thing to watch.

The debate

The bull case (steel-manned): This is turning into a heart-and-metabolism story, not a diet story, and that is a far bigger, stickier market. The new SURMOUNT-1 data (55% drop in CRP, 40% drop in insulin resistance at the top tirzepatide dose) lets doctors reframe these as "cardiometabolic health drugs" that could "far outdo statins," which means lifelong, guideline-driven, insurance-covered use. Penetration is already at "one in 10 U.S. adults" and the biology keeps opening new doors (heart, kidney, liver) because GLP-1 receptors sit on many cell types. Medicare just put a $50 price in front of seniors through 2027. Lilly is compounding as the clear leader, its pill is gaining on Novo, and it is aggressively defending its next-gen crown jewel (retatrutide) against copycats before launch. And there is "a trillion" in pharma acquisition firepower chasing the 2030 patent cliff, a bid under every credible fast-follower.

The bear case (steel-manned): Follow the commodity math. Even the bulls' favorite value idea (Novo) is cheap for one reason: "that patent cliff that falls off whenever the competition really ramps... when [medicine] gets totally commodified." The access system is fundamentally broken: "less than 2% of people in any given plan actually get access" through normal insurance, which is why employers and drugmakers are scrambling to build cheaper, direct-to-patient channels, and every one of those channels pushes the net price down. The products still have real problems the science underlines: "40%" of the weight lost is muscle, not fat, and the nausea drives people off. And the gray market is so large that Lilly is chasing "14,000 websites" across "100 countries" just to protect one unlaunched drug, evidence of how hard it is to hold a price when a molecule is this easy to copy.

My read (a framing, not a call): The useful exercise is to notice who the market listened to over the past two weeks, and it was investors and clinicians, not the drugmakers. Two threads sit in tension. The clinical thread (the CRP and heart data) is unambiguously bullish for volume: it converts a lifestyle drug into preventive medicine. The commercial thread (Medicare's $50 price, Andel's "$100 a fill," direct-to-patient channels, a black market Lilly cannot stamp out) is unambiguously bearish for price. Same drugs, opposite vectors. The number that still decides the whole thing is the one the podcasts keep dancing around and never hand us cleanly: net revenue per patient per year, sustained over time.

Stocks in play

Coverage was investor- and clinician-led rather than company-specific, so several names were discussed as investment ideas rather than through fresh company news. LLY and NVO are always covered; Stryker and Amgen are added because they were discussed by name.

Read-throughs

• Fast-followers (AMGN, VKTX, Roche): mixed. Amgen got a science nod, Viking a buyout mention, Roche silence. Amgen's MariTide is the interesting one: a diabetes/obesity podcast explained the "puzzling paradox" that both stimulating and blocking the GIP receptor can boost weight loss when paired with a GLP-1, and named "Maridebart cafraglutide" (MariTide) as the antagonist example, so the mechanism has genuine scientific backing even without new trial data (Diabetes Care "On Air," August 10). Viking Therapeutics surfaced only as a perennial buyout candidate in the "trillion in firepower" M&A discussion (Fidelity). Roche (CT-388/CT-996) went unmentioned again.
• The next-gen field keeps filling up (glucagon angle). A diabetes podcast added detail to the cervodotide Phase 3 result flagged earlier (about 12 to 13% weight loss at 76 weeks). Because cervodotide adds glucagon to the GLP-1, it "induces lipolysis... increases energy expenditure," and in a substudy delivered "an almost 65% reduction in liver fat," pointing it squarely at fatty-liver disease (MASH), and possibly at "non-responders to our current incretin-based medications" (DOC Updates, August 10). Another clinical education podcast offered a clean efficacy scoreboard: semaglutide "12–18%," tirzepatide "15–22% at 15 mg in SURMOUNT-1," oral orforglipron "12.4%" (Decera Clinical Education, August 11). More good drugs on the shelf is bearish for long-run pricing.
• Insurers, PBMs, employers (CVS, CI, UNH): the disintermediation trend is the story. No PBM was named directly, but the Andel interview is a pointed read-through: if "less than 2%" of covered members actually get a GLP-1 through the normal pharmacy-benefit process, and if Lilly and Novo are both opening their own direct-to-employer and direct-to-patient channels, the middleman's role in this category is shrinking (Off the Chart). Add the new Medicare "$50 through 2027" program, and the pricing power is migrating toward government and direct channels, away from the commercial PBM rebate model that CVS/Caremark, Cigna/Express Scripts and UNH/Optum Rx are built on.
• Compounding and gray market: the quality problem, quantified. A clinician-hosted podcast dissected a "secret shopper" study of online compounded-GLP-1 sellers: only "37%" asked for any clinical evidence (blood pressure, glucose, cholesterol), prescriptions came through "sometimes less than 5 minutes," credit cards were charged "before confirmation," the same shopper got "3 different prescriptions from 3 different sites," and sellers used "leading questions" to bolt on additives like B12 and exploit the "personalized compound" loophole, even though the drug shortage has ended and mass compounding is no longer legal, with the FDA now weighing an outright scale ban (Fat Science, August 10). The gray market that caps brand pricing is still wide open but looking legally shakier, a slow tailwind for the branded incumbents.
• Medtech and bariatric: covered indirectly via the Stryker idea above (aging-demographics device demand).
• Food, QSR, consumer: the "companion product" angle. A pharma-industry podcast explored the emerging "GLP-1 companion category," protein supplements, probiotics and products aimed at the GI side effects and fatigue of these drugs, arguing the drugs are "here to stay" and that established over-the-counter and nutrition companies are best positioned as this shelf consolidates (Citeline, August 17).

What changed vs last week

• Whose voice dominated flipped from operators to investors. The prior issue leaned on an access-platform CEO (Hims) and an adherence-platform CEO (Omada). The under-covered thread surfaced here is the investment community, a stock-picking show, a Fidelity portfolio manager, an investing podcast, plus clinicians. When the drugmakers stay off the mic, the market fills the space with its own read, and that read is "Lilly core long, Novo cheap-but-cliff-risk."
• New to this newsletter (all one to two weeks old): hard cardiometabolic biomarker data from SURMOUNT-1 (55% CRP reduction) reframing GLP-1s as heart drugs; specific numbers on Lilly's retatrutide enforcement (6 sued, 200+ referred, 14,000 sites, 100 countries); the Medicare "$50 through 2027" program and Andel's "less than 2% get access" and "$100 a fill" mechanics; a Novo-insider origin story with the "one in 10 U.S. adults" Gallup penetration figure; cervodotide's "65% liver-fat reduction" glucagon angle; and the compounding "secret shopper" quality data (only 37% asked for any clinical evidence).
• Confirmed and extended from prior weeks: the muscle-loss problem (a Fidelity PM independently put it at "40% of weight loss is lean muscle"); the Lilly-over-Novo leadership story (now restated by investors, not just commentators); the compounding channel remaining wide open despite the legal squeeze; and the 2030 patent cliff as the anchor of every price-decline argument.
• Faded, no follow-up: the Hims "$40–50" price call and WuXi "chokehold" story (the prior headliners) got no new coverage; the QSR read-through went quiet; no update on the UK safety scare from earlier issues.
• Still quiet (zero dedicated episodes): Novo Nordisk on its own merits (CagriSema, UBT-251, Capital Markets Day); Roche (CT-388/CT-996); pen and auto-injector suppliers; Western contract manufacturers (CTLT, LNZA, TMO) by name; specific state legislation; and, still, clean TRx/NRx prescription counts with a net price per script, the one dataset that would actually settle the bull and bear fight.

The center of gravity moved from "how cheap can these get" to "how big can the market get if these become heart drugs" (the SURMOUNT-1 data) versus "how fast does price fall as everyone builds direct channels" (Medicare's $50, Andel, the drugmakers' own storefronts). Volume up, price down, same tension, sharper edges.